MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Growing
The company is in a growing phase, with the latest annual income totaling USD 409.66K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 409.66K.
Overvalued
The company’s latest PE is -5.95, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.15M shares, increasing 10.05% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.